



Invest like a pro, with the pros.



www.capitalideasmedia.com

Morning Need to Know

Getting you ready for your investing day

February 12, 2021

Written & curated by the Capital Ideas Media team



CANADIAN ANALYSTS' CALLS

Calian Group Ltd. (TSX:CGY). Stifel Nicolaus Canada analysts maintained their “Buy” rating and \$80 per share target price on the stock, saying Calian offers tech investors an increasingly rare opportunity -- “attractive growth at a reasonable price.”

“Calian reported a solid Q1 with headline results beating consensus across the board, largely driven by 57% YoY growth in Healthcare and 19.5% YoY growth in Learning. Calian said that most of its core business is now back to pre-COVID levels, and that it continues to see upside in F2021, boosting its annual guidance

as a result,” they said.

“More importantly, Europe is now a major growth driver, up 253% YoY and now accounts for 10% of total revenue. Calian is seeing significant synergies with its recent acquisitions (i.e. SatService, CTS and Cadence) in the EU defense market. Calian also started a new patient support program in Europe and is looking to replicate its success across six different countries this year.”

goeasy Ltd. (TSX:GSY). Desjardins Securities analyst Gary Ho increased his target price to \$119 per share from \$99, while maintaining a “Buy” rating on the alternative financial services provider, saying he expects the Company to raise its dividend by 35 per cent and reintroduce a three-year outlook alongside the release of its fourth-quarter financial results on February 17.

“Our investment thesis is predicated on: (1) GSY has been able to successfully weather the pandemic and remains well-insulated with its loan protection insurance program; (2) management has shifted its focus more toward offence, suggesting growth through organic initiatives as well as potential M&A;

and (3) with scale, the business could consistently generate mid-20-per-cent ROE [return on equity],” the analyst wrote.



U.S. ANALYSTS' CALLS

QuantumScape Corporation (NYSE:QS). Morgan Stanley analyst Adam Jonas initiated coverage on the developer of solid-state battery technology for electric vehicles with an “Overweight” rating and a \$70 per share price target.

The analyst said that it is among companies in the electric vehicle battery space offering “the most compelling strategies” and positive risk/reward skews.

He added that the Company has been developing “game changing” solid state cell technology and has achieved “promising results” with its patent ceramic separator.

Trupanion, Inc. (NASDAQ:TRUP). Lake Street analyst Mark Argento raised his price target on the

provider of medical insurance for cats and dogs to \$150 per share from \$85, while keeping a “Buy” rating on the stock, after what he calls a “strong” Q4 “across all key metrics” and issuing guidance for FY21 growth above Street estimates.

He wrote that the company has been able to leverage its data, customer service, partner relationships, and software platform to widen its competitive moats since the pandemic began and continues to view Trupanion as a “growth story still in the early innings.”



STOCKS THAT MAY MOVE

Bausch Health Companies Inc. (TSX:BHC) stock looks set to open higher after billionaire activist investor Carl Icahn disclosed that he has accumulated a 7.83% stake in the healthcare company.

Enbridge Inc. (TSX:ENB) reported that its Q4 profit

surged 79% to \$1.78 billion on higher crude oil shipments.

MARKETS

S&P/TSX and U.S. equity futures are pointing to a lower open Friday on concerns about the spread of COVID-19 variants.

CURRENCIES

The Canadian dollar is down 0.18 at 0.7854 (U.S.).

COMMODITIES

West Texas Intermediate crude oil fell 0.8% at \$57.77.

Gold slipped 0.6% to \$1,816.30 an ounce.

Please email questions, comments or concerns to:

customercare@capitalideasresearch.com

Access, insight and ideas.

Capital Ideas Media Team

www.capitalideasmedia.com



The information and recommendations made available here (“Information”) by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don't consider buying or selling any stock without conducting your own due diligence.

You are receiving this email because you are part of our investment network.

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Capital Ideas Research · HSBC Bank Place · 10250 101 Street Suite 1803 · Edmonton, Alberta T5G 3P4 · Canada